Cargando…
1221. Non-severe, non-immune mediated intolerances: simple targets for direct non-invasive delabeling opportunities of beta-lactam antibiotic allergy labels (BAAL)
BACKGROUND: Majority of patients with a BAALs can tolerate a β-lactam without concerns for a severe IgE-mediated reaction. Many BAALs are confirmed to be intolerances or adverse events versus a true allergy. False BAALs can result in the use of alternative non-BLs, posing risk for collateral health...
Autores principales: | Polisetty, Radhika S, Dickens, Michael, Tran, Hoang, Khankan, Nour, Weslander, Erin, Bertram, Christie M, Moore, William J, Wang, Sheila K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678977/ http://dx.doi.org/10.1093/ofid/ofad500.1061 |
Ejemplares similares
-
1237. Inpatients with a beta-lactam antibiotic allergy label (BAAL) and unrevealed tolerance: A prevalence study aimed to prioritize non-invasive delabeling for antimicrobial stewardship programs
por: Dickens, Michael, et al.
Publicado: (2023) -
Approach for delabeling beta-lactam allergy in children
por: Sáenz de Santa María, R., et al.
Publicado: (2023) -
β‐Lactam allergy testing and delabeling—Experiences and lessons from Singapore
por: Heng, Yee Kiat, et al.
Publicado: (2020) -
Delabeling, safety, and impact of β-lactam allergy testing: A systematic review
por: Loprete, Jacqueline, et al.
Publicado: (2023) -
Penicillin allergy delabelling in pregnancy
por: Atkinson, Andrea, et al.
Publicado: (2023)